Parkinson's DiseaseMelvin David Yahr, Kenneth J. Bergmann |
Contents
Pathology of Parkinsons Disease | 1 |
Reiriz J 481 | 15 |
Biochemical Pathophysiology of Parkinsons Disease | 19 |
Copyright | |
90 other sections not shown
Common terms and phrases
activity agonists akinesia Alzheimer's amine basal ganglia binding sites biochemical Brain Res bromocriptine carbidopa catecholamine caudate nucleus cells cerebral cholinergic chronic clinical correlation cortical decrease dementia deprenyl depression disability disorders dopa dopamine receptors dopaminergic dose drug dyskinesia dystonia edited effects enzyme function GABA Hornykiewicz human brain idiopathic increase inhibition inhibitors K. J. Bergmann L-deprenyl L-DOPA lesions levels levodopa Lewy bodies lisuride M. D. Yahr MAO-A MAO-B ment metabolism metabolites mg/kg monkey monoamine oxidase motor movements MPP+ MPTP Neurology neurons neurotoxicity nigrostriatal normal onset Parkin Parkinson's disease parkinsonian patients patients with Parkinson's PD patients pergolide Pharmacol plasma postural progressive supranuclear palsy putamen rat brain Raven Press response score significant son's disease striatal striatum substantia nigra symptoms syndrome Table therapy tients tion tissue toxicity treatment tremor tyramine uptake Yahr and K. J. York